Specifically, in over 30% of patients with lower grade astrocytoma, new deletion of PTEN, CDKN2A, CDKN2B, or amplification of CDK6 and gain of KRAS were detected (Fig. 4a), which is consistent with previous reports10. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).